USA - New York Stock Exchange - NYSE:RMD - US7611521078 - Common Stock
The current stock price of RMD is 253.25 USD. In the past month the price increased by 1.42%. In the past year, price increased by 2.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.09B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.25 | 202.22B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.41 | 150.49B | ||
| SYK | STRYKER CORP | 28.24 | 142.25B | ||
| IDXX | IDEXX LABORATORIES INC | 58.68 | 59.09B | ||
| BDX | BECTON DICKINSON AND CO | 13.36 | 55.21B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.45 | 49.88B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.35 | 36.28B | ||
| DXCM | DEXCOM INC | 34.28 | 24.87B | ||
| PODD | INSULET CORP | 69.33 | 22.29B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.97 | 19.19B | ||
| HOLX | HOLOGIC INC | 17.56 | 16.71B |
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,600 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
RESMED INC
9001 Spectrum Center Blvd
San Diego CALIFORNIA 92123 US
CEO: MichaelJ.Farrell
Employees: 9980
Phone: 18587462400
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,600 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
The current stock price of RMD is 253.25 USD. The price decreased by -1.01% in the last trading session.
RESMED INC (RMD) has a dividend yield of 0.94%. The yearly dividend amount is currently 2.12.
RMD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
RMD stock is listed on the New York Stock Exchange exchange.
RESMED INC (RMD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
RESMED INC (RMD) will report earnings on 2026-01-28.
ChartMill assigns a technical rating of 3 / 10 to RMD. When comparing the yearly performance of all stocks, RMD is a bad performer in the overall market: 61.91% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to RMD. Both the health and profitability get an excellent rating, making RMD a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months RMD reported a non-GAAP Earnings per Share(EPS) of 9.9. The EPS increased by 19.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.35% | ||
| ROA | 17.31% | ||
| ROE | 23.49% | ||
| Debt/Equity | 0.07 |
25 analysts have analysed RMD and the average price target is 299.44 USD. This implies a price increase of 18.24% is expected in the next year compared to the current price of 253.25.
For the next year, analysts expect an EPS growth of 14.89% and a revenue growth 9.2% for RMD